No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Wednesday, October 1, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Stock Market

Hong Kong’s Regencell Bioscience triples in latest surge for a speculative stock

by TheAdviserMagazine
4 months ago
in Stock Market
Reading Time: 4 mins read
A A
Hong Kong’s Regencell Bioscience triples in latest surge for a speculative stock
Share on FacebookShare on TwitterShare on LInkedIn


Hong Kong Skyline

Nikada | E+ | Getty Images

Regencell Bioscience Holdings, an early-stage, Hong Kong-based bioscience company with no revenue, is the latest speculative overseas stock to attract an unusual surge in trading demand.

Shares of Regencell, which says it develops traditional Chinese herb treatments to treat childhood attention deficit hyperactivity disorder and autism, more than tripled on Monday — soaring more than 280% by the close. A 38-for-1 split declared on June 2 took effect on Monday.

The company’s year to date performance is off the charts too, having risen 46,000% in 2025. By Monday’s close, Regencell, founded in 2014 and traded on Nasdaq under the ticker ‘RGC’ since 2021, had a total market capitalization of $29.7 billion, according to S&P Capital IQ.

Regencell CEO Yat-Gai Au controls 86.24% of the total number of shares outstanding, according to FactSet data.

Stock Chart IconStock chart icon

Regencell Bioscience Holdings in 2025.

Regencell is the latest example of a speculative international stock attracting attention during summer trading. In August, 2022, for example, AMTD Digital, a Hong Kong-based fintech company, climbed 126%, briefly giving it a market value greater than Coca-Cola and Bank of America.

Regencell’s market value is now about equal with Nasdaq-traded Lululemon and tops Super Micro Computer and Fifth Third Bancorp.

Earlier this month, Regencell explained the stock split as designed solely “to enhance liquidity in the market for the company’s ordinary shares and make the shares more accessible to investors.” Stock splits do not change anything fundamentally about a company.

Regencell’s surge also came amid an increased focus on alternative medicines after Robert F. Kennedy Jr. was sworn in as Secretary of the U.S. Department of Health and Human Services in February. Kennedy, a vaccine skeptic, has taken steps to discourage routine immunizations in the U.S., last week removing all of the members of a panel that advises the Centers for Disease Control and Prevention on vaccines.

Regencell’s stock often makes huge one-day swings. For example, shares jumped roughly 30% on March 21, before dropping 30% the following trading day.

Obscure treatments, zero revenue

In spite of the wild spike in the stock, little is known about the efficacy and commercialization of the Regencell’s treatments for ADHD and Autistic Spectrum Disorders.

Regencell’s business centers on a proprietary Traditional Chinese Medicine formula (TCM) developed in a partnership with TCM practitioner Sik-Kee Au using his “Sik-Kee Au TCM Brain Theory.” Sik-Kee Au is the father of the Regencell chief executive officer Yat-Gai Au, the company said in a 2022 statement.

Three liquid-based, orally TCM formulae candidates claim to address mild, moderate and severe conditions and only contain natural ingredients such as so-called “detoxication herbs,” blood circulation herbs and digestion herbs.

“These TCM formulae form the basis of our TCM product candidates, which we intend to develop and commercialize for the treatment of ADHD and ASD,” Regencell’s website reads.

In its latest annual report filed last October, Regencell said that it had not generated any revenue, nor filed for any regulatory approvals of its TCM formulas. For the fiscal years ended June 2024 and 2023, Regencell incurred total net losses of $4.36 million and $6.06 million, respectively, according to a 20F filing to the SEC.

“We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable,” read the filing.

Regencell has not responded to a CNBC request for comment.

Regencell’s latest patient case study, dated Nov. 15, 2023, said 28 patients were given the treatment over a period of three months in a second efficacy trial and showed an improvement in symptoms of ADHD and ASD, according to the company’s webpage.

In an earlier case, Regencell said in a 2021 news release that it treated a dozen patients with suspected or confirmed Covid-19 cases, using a modified version of Au’s modified proprietary cold and flu TCM formula. What was described as an improvement of Covid conditions led Regencell to form a joint venture with Honor Epic Enterprises Limited in Sept. 2021 to conduct further tests and commercialize the company’s Covid treatment in ASEAN countries, according to the statement.

Online buzz

The stock has attracted little chatter on social media over the past few years. Those comments that have been made suggest both retail trader enthusiasm — and skepticism.

One user on the Reddit page “r/Shortsqueeze” wrote on Monday that Regencell is “trading like a meme coin. Bought a little to see what happens and it dropped 50% right after lol.” Another user said in a post made three months ago, “I scalp RGC everyday for a bit of profit.” The stock jumped 1,360% in May alone.

On LinkedIn in May, one investor said he “can’t stop laughing,” after reading the company description. Another post from a user in the pharmaceutical industry, according to his profile, last week said Regencell has become the “stock to watch” after its spike in May on “no official news or catalysts.” Another LinkedIn user last month commented on Regencell, saying, “China based, low volume and no official news, bizarro.”

On X, one user wrote in a Monday post said, “for #CompleteBullsh__CompanyOfTheYear I nominate regencell.”

— CNBC’s Scott Schnipper contributed reporting.



Source link

Tags: BioscienceHongKongslatestRegencellspeculativestocksurgeTriples
ShareTweetShare
Previous Post

Wefox wraps up sale of Italian operations to J.C. Flowers

Next Post

Bitcoin User Accidentally Sent $60,000 in Fees—Don’t Make the Same Mistake

Related Posts

edit post
How Credit Card Balance Transfers Work: Save on Debt

How Credit Card Balance Transfers Work: Save on Debt

by TheAdviserMagazine
September 25, 2025
0

Americans are carrying over $1 trillion in credit card debt, according to the Federal Reserve. With average annual percentage rates...

edit post
Top Picks to Build Credit

Top Picks to Build Credit

by TheAdviserMagazine
September 25, 2025
0

For many college students, getting a first credit card is a major step toward financial independence. Used wisely, student credit...

edit post
The #1 Wealth Habit Young People Skip — and How to Fix It

The #1 Wealth Habit Young People Skip — and How to Fix It

by TheAdviserMagazine
September 23, 2025
0

If you ask most people what it takes to build wealth, you’ll probably hear some version of: “Get a good...

edit post
What TikTok Star Earnings Teach Us About Investing

What TikTok Star Earnings Teach Us About Investing

by TheAdviserMagazine
September 16, 2025
0

Charli D’Amelio posted her first TikTok at 15. Fast-forward a few years and she’s earning millions from brand deals, appearances,...

edit post
How to Invest for a Child

How to Invest for a Child

by TheAdviserMagazine
September 11, 2025
0

When it comes to securing your child’s financial future, choosing the best UGMA/UTMA accounts is crucial. In this article, we’ll...

edit post
Most Expensive Engagement Rings in Hollywood (and How Much to Save to Buy Them)

Most Expensive Engagement Rings in Hollywood (and How Much to Save to Buy Them)

by TheAdviserMagazine
September 11, 2025
0

Grace Kelly’s Cartier diamond. Mariah Carey’s 35-carat sparkler. Kim Kardashian’s flawless cushion-cut stone. These aren’t just engagement rings—they’re symbols of...

Next Post
edit post
Bitcoin User Accidentally Sent ,000 in Fees—Don’t Make the Same Mistake

Bitcoin User Accidentally Sent $60,000 in Fees—Don’t Make the Same Mistake

edit post
Sequoia-backed Crosby launches a new kind of AI-powered law firm

Sequoia-backed Crosby launches a new kind of AI-powered law firm

  • Trending
  • Comments
  • Latest
edit post
What Happens If a Spouse Dies Without a Will in North Carolina?

What Happens If a Spouse Dies Without a Will in North Carolina?

September 14, 2025
edit post
California May Reimplement Mask Mandates

California May Reimplement Mask Mandates

September 5, 2025
edit post
Who Needs a Trust Instead of a Will in North Carolina?

Who Needs a Trust Instead of a Will in North Carolina?

September 1, 2025
edit post
Does a Will Need to Be Notarized in North Carolina?

Does a Will Need to Be Notarized in North Carolina?

September 8, 2025
edit post
DACA recipients no longer eligible for Marketplace health insurance and subsidies

DACA recipients no longer eligible for Marketplace health insurance and subsidies

September 11, 2025
edit post
‘Quiet luxury’ is coming for the housing market, The Corcoran Group CEO says. It’s not just the Hamptons, Aspen, and Miami anymore

‘Quiet luxury’ is coming for the housing market, The Corcoran Group CEO says. It’s not just the Hamptons, Aspen, and Miami anymore

September 9, 2025
edit post
Trump’s high tariffs on several countries to hold back US economic growth: Harvard economist Kenneth Rogoff

Trump’s high tariffs on several countries to hold back US economic growth: Harvard economist Kenneth Rogoff

0
edit post
We’re not in an ‘AI winter’—but here’s how to survive a cold snap

We’re not in an ‘AI winter’—but here’s how to survive a cold snap

0
edit post
The Real Jan. 6th Coup

The Real Jan. 6th Coup

0
edit post
XRP Price Jumps As Bloomberg Says XRP ETF Approval Certain

XRP Price Jumps As Bloomberg Says XRP ETF Approval Certain

0
edit post
The Social Security Fairness Act—Who Wins and Who Loses If It Passes?

The Social Security Fairness Act—Who Wins and Who Loses If It Passes?

0
edit post
Odds of a government shutdown rise to 70% in prediction markets

Odds of a government shutdown rise to 70% in prediction markets

0
edit post
We’re not in an ‘AI winter’—but here’s how to survive a cold snap

We’re not in an ‘AI winter’—but here’s how to survive a cold snap

October 1, 2025
edit post
Trump’s high tariffs on several countries to hold back US economic growth: Harvard economist Kenneth Rogoff

Trump’s high tariffs on several countries to hold back US economic growth: Harvard economist Kenneth Rogoff

October 1, 2025
edit post
Sunny Agrawal flags overpriced unlisted stocks amid IPO frenzy

Sunny Agrawal flags overpriced unlisted stocks amid IPO frenzy

October 1, 2025
edit post
Stablecoin Crackdown: European Central Bank Gathers Backing For Joint Issuance Ban

Stablecoin Crackdown: European Central Bank Gathers Backing For Joint Issuance Ban

September 30, 2025
edit post
Gold hovers near record high on US shutdown concerns, Fed rate outlook

Gold hovers near record high on US shutdown concerns, Fed rate outlook

September 30, 2025
edit post
Britain Vs Florida | Armstrong Economics

Britain Vs Florida | Armstrong Economics

September 30, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • We’re not in an ‘AI winter’—but here’s how to survive a cold snap
  • Trump’s high tariffs on several countries to hold back US economic growth: Harvard economist Kenneth Rogoff
  • Sunny Agrawal flags overpriced unlisted stocks amid IPO frenzy
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.